{"id":"cpl-01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, CPL-01 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"CPL-01 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:52.105Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07490496","phase":"PHASE3","title":"Phase 3 Bunionectomy Study","status":"NOT_YET_RECRUITING","sponsor":"Cali Pharmaceuticals LLC","startDate":"2026-07-01","conditions":"Postoperative Pain, Bunion","enrollment":112},{"nctId":"NCT05831449","phase":"PHASE3","title":"CPL-01 in the Management of Postoperative Pain After Bunionectomy","status":"COMPLETED","sponsor":"Cali Pharmaceuticals LLC","startDate":"2023-05-22","conditions":"Bunion","enrollment":616},{"nctId":"NCT05813847","phase":"PHASE3","title":"Herniorrhaphy for Postoperative Pain","status":"COMPLETED","sponsor":"Cali Pharmaceuticals LLC","startDate":"2023-04-18","conditions":"Hernia, Inguinal","enrollment":518},{"nctId":"NCT05411861","phase":"PHASE2","title":"Post-Operative Pain and Opioid Reduction Trial After Bunionectomy","status":"COMPLETED","sponsor":"Cali Pharmaceuticals LLC","startDate":"2022-06-14","conditions":"Hallux Valgus and Bunion","enrollment":73},{"nctId":"NCT04182880","phase":"PHASE2","title":"Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain","status":"COMPLETED","sponsor":"Cali Pharmaceuticals LLC","startDate":"2020-01-06","conditions":"Abdominoplasty","enrollment":20},{"nctId":"NCT05080959","phase":"PHASE2","title":"A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy","status":"COMPLETED","sponsor":"Cali Pharmaceuticals LLC","startDate":"2021-07-28","conditions":"Inguinal Herniorrhaphy","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Infiltration of study drug"],"phase":"phase_3","status":"active","brandName":"CPL-01","genericName":"CPL-01","companyName":"Cali Pharmaceuticals LLC","companyId":"cali-pharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CPL-01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}